Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review)

Soeiro‑de‑Souza,Márcio G.; Dias,Vasco Videira; Missio,Giovanni; Balanzá‑Martinez,Vicent; Valiengo,Leandro; Carvalho,André F.; Moreno,Ricardo Alberto

doi:10.3892/etm.2015.2213

Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review)

Authors:
- Márcio G. Soeiro‑de‑Souza
- Vasco Videira Dias
- Giovanni Missio
- Vicent Balanzá‑Martinez
- Leandro Valiengo
- André F. Carvalho
- Ricardo Alberto Moreno
View Affiliations

Affiliations: Mood Disorders Unit (GRUDA), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil, University Hospital Doctor Peset and Section of Psychiatry, University of Valencia, Valencia, Spain, Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil, Psychiatry Research Group and Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Brazil
Published online on: January 23, 2015 https://doi.org/10.3892/etm.2015.2213
Pages: 643-652

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present review was to discuss the following aspects of treatment with quetiapine in psychiatric disorders: i) Neurocognition and functional recovery in bipolar disorder (BD); ii) neuroprotective profile in different models; and iii) potential off‑label indications. A PubMed search was conducted of articles published in English between 2000 and 2012 on quetiapine, cross‑referenced with the terms ‘anxiety’, ‘attention deficit disorder’, ‘borderline personality disorder’, ‘dementia’, ‘insomnia’, ‘major depressive disorder’ (MDD), ‘obsessive‑compulsive disorder’, ‘post‑traumatic stress disorder’, ‘remission’, ‘cognition’, ‘neurobiology’, ‘neuroprotection’, ‘efficacy’ and ‘effectiveness’. Articles were selected from meta‑analyses, randomized clinical trials and open trials, and the results were summarized. Quetiapine, when studied in off‑label conditions, has shown efficacy as a monotherapy in MDD and general anxiety disorder. Quetiapine also appears to exhibit a small beneficial effect in dementia. The review of other conditions was affected by methodological limitations that precluded any definitive conclusions on the efficacy or safety of quetiapine. Overall, the present review shows evidence supporting a potential role for quetiapine in improving cognition, functional recovery and negative symptoms in a cost‑effective manner in BD. These benefits of quetiapine are potentially associated with its well‑described neuroprotective effects; however, further studies are clearly warranted.

View Figures

View References

1	Xu H, Wang H, Zhuang L, Yan B, Yu Y, Wei Z, et al: Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer’s disease. FEBS J. 275:3718–3728
2	Murray CJL and López AD: The Global Burden of Disease. Harvard School of Public Health; Boston, MA: 1996
3	Bi X, Zhang Y, Yan B, Fang S, He J, Zhang D, et al: Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice. J Neurochem. 123:14–20. 2012. View Article : Google Scholar : PubMed/NCBI
4	Fagiolini A, Kupfer DJ, Masalehdan A, Scott JA, Houck PR and Frank E: Functional impairment in the remission phase of bipolar disorder. Bipolar Disord. 7:281–285. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sierra P, Livianos L and Rojo L: Quality of life for patients with bipolar disorder: relationship with clinical and demographic variables. Bipolar Disord. 7:159–165. 2005. View Article : Google Scholar : PubMed/NCBI
6	Artigas F: Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol. S0924-977X(13)00144-2. 2013. View Article : Google Scholar : PubMed/NCBI
7	Prieto E, Micó JA, Meana JJ and Majadas S: Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder. Actas Esp Psiquiatr. 38:22–32. 2010.PubMed/NCBI
8	Fumagalli F, Molteni R, Bedogni F, et al: Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport. 15:2109–2112. 2004. View Article : Google Scholar : PubMed/NCBI
9	López-Muñoz F and Alamo C: Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry. 4:1022013. View Article : Google Scholar : PubMed/NCBI
10	Park SW, Lee SK, et al: Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett. 2:25–29. 2006. View Article : Google Scholar
11	El-Khalili N: Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders. Neuropsychiatr Dis Treat. 8:523–536. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Zhang H, Wang L, Jiang W, Xu H, Xiao L, et al: Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr Res. 138:8–17. 2012. View Article : Google Scholar : PubMed/NCBI
13	Buckley PF: Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin. 20:1357–1363. 2004. View Article : Google Scholar : PubMed/NCBI
14	Leucht S, Kissling W and Davis JM: Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 39:1591–1602. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Xu H, Jiang W, Xiao L, Yan B, He J, et al: Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr Res. 106:182–191. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompré PP and Stip E: Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 26:183–192. 2011. View Article : Google Scholar : PubMed/NCBI
17	Grande I, Kapczinski F, Stertz L, Colpo GD, Kunz M, Cereser KM, et al: Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res. 46:1511–1514. 2012. View Article : Google Scholar : PubMed/NCBI
18	Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 66:111–121. 2005. View Article : Google Scholar : PubMed/NCBI
19	McIntyre RS, Brecher M, Paulsson B, Huizar K and Mullen J: Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 15:573–585. 2005. View Article : Google Scholar : PubMed/NCBI
20	Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Katsuki A, Hayashi K, et al: Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 34:308–312. 2010. View Article : Google Scholar
21	Vieta E, Suppes T, Eggens I, Persson I, Paulsson B and Brecher M: Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 109:251–263. 2008. View Article : Google Scholar : PubMed/NCBI
22	Suppes T, Vieta E, Liu S, Brecher M and Paulsson B; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 166:476–488. 2009. View Article : Google Scholar : PubMed/NCBI
23	Nikisch G, Baumann P, Liu T and Mathé AA: Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Int J Neuropsychopharmacol. 15:1051–1061. 2012. View Article : Google Scholar
24	Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J and Brecher M: Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 70:540–549. 2009. View Article : Google Scholar : PubMed/NCBI
25	Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J and Eriksson H; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 14:299–313. 2009.PubMed/NCBI
26	Calabrese JR, Keck PE, Macfadden W Jr, Minkwitz M, Ketter TA, Weisler RH, et al: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 162:1351–1360. 2005. View Article : Google Scholar : PubMed/NCBI
27	Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 26:600–609. 2006. View Article : Google Scholar : PubMed/NCBI
28	Padurariu M, Ciobica A, Dobrin I and Stefanescu C: Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 479:317–320. 2010. View Article : Google Scholar : PubMed/NCBI
29	Endicott J, Rajagopalan K, Minkwitz M and Macfadden W; BOLDER Study Group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol. 22:29–37. 2007.
30	Endicott J, Paulsson B, Gustafsson U, Schiöler H and Hassan M: Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. J Affect Disord. 111:306–319. 2008. View Article : Google Scholar : PubMed/NCBI
31	Chang K, Delbello M, Chu WJ, Garrett A, Kelley R, Mills N, et al: Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression. J Child Adolesc Psychopharmacol. 22:261–268. 2012. View Article : Google Scholar : PubMed/NCBI
32	Dell’Osso B, Arici C, Dobrea C, Benatti B and Altamura AC: Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. Int Clin Psychopharmacol. 27:310–313. 2012.
33	Connor DF, McLaughlin TJ and Jeffers-Terry M: Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 18:140–156. 2008. View Article : Google Scholar : PubMed/NCBI
34	Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE and Dunn DW: Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 17:334–347. 2007. View Article : Google Scholar : PubMed/NCBI
35	Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M and Eriksson H: Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 29:574–586. 2012. View Article : Google Scholar : PubMed/NCBI
36	Weisler RH, Montgomery SA, Earley WR, Szamosi J and Lazarus A: Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 27:27–39. 2012. View Article : Google Scholar
37	Komossa K, Rummel-Kluge C, Schmid F, et al: Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 1:CD0066252010.PubMed/NCBI
38	Bauer M, El-Khalili N, Datto C, Szamosi J and Eriksson H: A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 127:19–30. 2010. View Article : Google Scholar : PubMed/NCBI
39	Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D and Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 27:964–976. 2010. View Article : Google Scholar : PubMed/NCBI
40	Endicott J, Svedsäter H and Locklear JC: Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 8:301–311. 2012. View Article : Google Scholar : PubMed/NCBI
41	Mezhebovsky I, Mägi K, She F, Datto C and Eriksson H: Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 28:615–625. 2013. View Article : Google Scholar
42	Stein DJ, Bandelow B, Merideth C, et al: Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 26:614–628. 2011. View Article : Google Scholar : PubMed/NCBI
43	Merideth C, Cutler AJ, She F and Eriksson H: Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 27:40–54. 2012. View Article : Google Scholar
44	Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I and Eriksson H: A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 31:418–428. 2011. View Article : Google Scholar : PubMed/NCBI
45	Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, et al: Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 28:147–155. 2008. View Article : Google Scholar : PubMed/NCBI
46	Perrella C, Carrus D, Costa E and Schifano F: Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 31:158–163. 2007. View Article : Google Scholar
47	Byers MG, Allison KM, Wendel CS and Lee JK: Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol. 30:225–229. 2010. View Article : Google Scholar : PubMed/NCBI
48	Savas HA, Yumru M and Ozen ME: Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin Drug Investig. 28:439–442. 2008. View Article : Google Scholar : PubMed/NCBI
49	Yatham LN, Kennedy SH, Parikh SV, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 14:1–44. 2013. View Article : Google Scholar
50	Kozaric-Kovacic D and Pivac N: Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol. 10:253–261. 2007. View Article : Google Scholar
51	Palmer BW, Dawes SE and Heaton RK: What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev. 19:365–384. 2009. View Article : Google Scholar : PubMed/NCBI
52	Ahearn EP, Mussey M, Johnson C, Krohn A and Krahn D: Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharmacol. 21:29–33. 2006. View Article : Google Scholar
53	Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Singh B, et al: World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 100:20–38. 2008. View Article : Google Scholar : PubMed/NCBI
54	Sokolski KN, Denson TF, Lee RT and Reist C: Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil Med. 168:486–489. 2003.PubMed/NCBI
55	Torrent C, Martinez-Aran A, Daban C, Amann B, Balanzá-Martínez V, Del Mar Bonnín C, et al: Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry. 52:613–622. 2011. View Article : Google Scholar : PubMed/NCBI
56	Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG and Lorberbaum JP: Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 23:15–20. 2003. View Article : Google Scholar : PubMed/NCBI
57	Biskin RS and Paris J: Management of borderline personality disorder. CMAJ. 184:1897–1902. 2012. View Article : Google Scholar : PubMed/NCBI
58	Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, et al: Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 257:360–370. 2007. View Article : Google Scholar : PubMed/NCBI
59	Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, et al: Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 25:116–125. 2010. View Article : Google Scholar : PubMed/NCBI
60	Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, et al: Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res. 96:146–155. 2007. View Article : Google Scholar : PubMed/NCBI
61	Woodward ND, Purdon SE, Meltzer HY and Zald DH: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 8:457–472. 2005. View Article : Google Scholar : PubMed/NCBI
62	Bilder RM, Goldman RS, Volavka J, Czobor P, et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 159:1018–1028. 2002. View Article : Google Scholar : PubMed/NCBI
63	Harvey PD, Patterson TL, Potter LS, Zhong K and Brecher M: Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 163:1918–1925. 2006. View Article : Google Scholar : PubMed/NCBI
64	Robles O, Zabala A, Bombín I, Parellada M, Moreno D, Ruiz-Sancho A, et al: Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophr Bull. 37:405–415. 2011. View Article : Google Scholar :
65	Van den Eynde F, De Saedeleer S, Naudts K, Day J, Vogels C, van Heeringen C, et al: Quetiapine treatment and improved cognitive functioning in borderline personality disorder. Hum Psychopharmacol. 24:646–649. 2009. View Article : Google Scholar : PubMed/NCBI
66	Gvirts HZ, Harari H, Braw Y, Shefet D, Shamay-Tsoory SG and Levkovitz Y: Executive functioning among patients with borderline personality disorder (BPD) and their relatives. J Affect Disord. 143:261–264. 2012. View Article : Google Scholar : PubMed/NCBI
67	Dias VV, Balanzá-Martínez V, Soeiro-de-Souza MG, Moreno RA, Figueira ML, Machado-Vieira R, et al: Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand. 126:315–331. 2012. View Article : Google Scholar : PubMed/NCBI
68	Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA and Engelhart LM: Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry. 68:1186–1194. 2007. View Article : Google Scholar : PubMed/NCBI
69	Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A and Tsai AC: Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 10:e10014032013. View Article : Google Scholar : PubMed/NCBI
70	Asmal L, Flegar SJ, Wang J, et al: Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 11:CD0066252013.PubMed/NCBI
71	Tohen M, Zarate CA Jr, Hennen J, Khalsa H, Strakowski SM, Gebre-Medhin P, et al: The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 160:2099–2107. 2003. View Article : Google Scholar : PubMed/NCBI
72	Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, et al: Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry. 168:831–819. 2011. View Article : Google Scholar : PubMed/NCBI
73	Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC and Chatterton ML: Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics. 30:513–530. 2012. View Article : Google Scholar : PubMed/NCBI
74	Paleacu D, Barak Y, Mirecky I and Mazeh D: Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer’s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 23:393–400. 2008. View Article : Google Scholar
75	Zarate CA Jr: Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry. 61:52–61. 2000.PubMed/NCBI
76	Zhong KX, Tariot PN, Mintzer J, Minkwitz MC and Devine NA: Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 4:81–93. 2007. View Article : Google Scholar : PubMed/NCBI
77	Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, et al: Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 14:767–776. 2006. View Article : Google Scholar : PubMed/NCBI
78	Sajatovic M, Mullen JA and Sweitzer DE: Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry. 63:1156–1163. 2002. View Article : Google Scholar
79	Savaskan E, Schnitzler C, Schröder C, Cajochen C, Müller-Spahn F and Wirz-Justice A: Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer’s disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol. 9:507–516. 2006. View Article : Google Scholar
80	Tamayo JM, Zarate CA Jr, Vieta E, Vázquez G and Tohen M: Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 13:813–832. 2010. View Article : Google Scholar : PubMed/NCBI
81	Cheung G and Stapelberg J: Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials. NZ Med J. 124:39–50. 2011.
82	Miljević Č, Nikolić-Kokić A, Nikolić M, Niketić V, Spasić MB, Lečić-Toševski D, et al: Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study). Hum Psychopharmacol. 28:1–6. 2013. View Article : Google Scholar
83	LaLonde CD and Van Lieshout RJ: Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 31:326–333. 2011. View Article : Google Scholar : PubMed/NCBI
84	Altamura AC, Serati M, Buoli M and Dell’Osso B: Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 26:201–205. 2011. View Article : Google Scholar : PubMed/NCBI
85	Wang H, Xu H, Dyck LE and Li X-M: Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide (25–35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res. 81:572–580. 2005. View Article : Google Scholar : PubMed/NCBI
86	Vaishnavi S, Alamy S, Zhang W, Connor KM and Davidson JR: Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 31:1464–469. 2007. View Article : Google Scholar : PubMed/NCBI
87	Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, et al: The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry. 32:42–48. 2008. View Article : Google Scholar
88	Tassniyom K, Paholpak S, Tassniyom S and Kiewyoo J: Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 93:729–734. 2010.PubMed/NCBI
89	Kim H, Bang J, Chang HW, Kim JY, Park KU, Kim SH, et al: Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol. 678:55–60. 2012. View Article : Google Scholar : PubMed/NCBI
90	Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A and Marchand S: Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol. 32:684–687. 2012. View Article : Google Scholar : PubMed/NCBI
91	Luo C, Xu H and Li XM: Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 1063:32–39. 2005. View Article : Google Scholar : PubMed/NCBI
92	Hidalgo J, Rico-Villademoros F and Calandre EP: An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 31:71–77. 2007. View Article : Google Scholar
93	Craig D, Mirakhur A, Hart DJ, McIlroy SP and Passmore AP: A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry. 13:460–468. 2005. View Article : Google Scholar : PubMed/NCBI
94	Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 355:1525–1538. 2006. View Article : Google Scholar : PubMed/NCBI
95	Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al: Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ. 330:8742005. View Article : Google Scholar
96	Diniz JB, Shavitt RG, Fossaluza V, et al: A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 31:763–768. 2011. View Article : Google Scholar : PubMed/NCBI
97	Bogan AM, Koran LM, Chuong HW, Vapnik T and Bystritsky A: Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry. 66:73–79. 2005. View Article : Google Scholar : PubMed/NCBI
98	Sevincok L and Topuz A: Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 23:448–450. 2003.PubMed/NCBI
99	Denys D, van Megen H and Westenberg H: Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 63:700–703. 2002. View Article : Google Scholar : PubMed/NCBI
100	Misri S and Milis L: Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation. J Clin Psychopharmacol. 24:624–627. 2004. View Article : Google Scholar : PubMed/NCBI
101	Matsunaga H, Nagata T, Hayashida K, et al: A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 70:863–868. 2009. View Article : Google Scholar : PubMed/NCBI
102	Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 306:1359–1369. 2011. View Article : Google Scholar : PubMed/NCBI
103	Hirschfeld RMA, Weisler RH, Raines SR and Macfadden W; BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 67:355–362. 2006. View Article : Google Scholar : PubMed/NCBI
104	Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M and Brecher M: Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 70:526–539. 2009. View Article : Google Scholar : PubMed/NCBI
105	El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al: Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 13:917–932. 2010. View Article : Google Scholar : PubMed/NCBI
106	Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, et al: A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 23:269–275. 2008. View Article : Google Scholar : PubMed/NCBI
107	McIntyre A, Gendron A and McIntyre A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 24:487–494. 2007. View Article : Google Scholar
108	Chaput Y, Magnan A and Gendron A: The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry. 8:732008. View Article : Google Scholar : PubMed/NCBI
109	Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, et al: Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 69:603–608. 2008. View Article : Google Scholar : PubMed/NCBI
110	Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, et al: Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 193:485–492. 2008. View Article : Google Scholar : PubMed/NCBI
111	Shafti SS and Shahveisi B: Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol. 30:44–47. 2010. View Article : Google Scholar : PubMed/NCBI
112	Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al: Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 163:833–838. 2006. View Article : Google Scholar : PubMed/NCBI
113	Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, et al: A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol (Oxford). 22:417–425. 2008. View Article : Google Scholar
114	Steinberg M and Lyketsos CG: Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 169:900–906. 2012. View Article : Google Scholar : PubMed/NCBI
115	Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, et al: Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer’s disease. Dement Geriatr Cogn Disord. 31:218–214. 2011. View Article : Google Scholar
116	Richter T, Meyer G, Möhler R and Köpke S: Psychosocial interventions for reducing antipsychotic medication in care home residents. Cochrane Database Syst Rev. 12:CD0086342012.PubMed/NCBI
117	Ballard Cv and Corbett A: Agitation and aggression in people with Alzheimer’s disease. Curr Opin Psychiatry. 26:252–259. 2013. View Article : Google Scholar : PubMed/NCBI
118	Suppes T, Datto C, et al: Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 15:485–493. 2014. View Article : Google Scholar